Patents Assigned to Pfizer
  • Substituted-aryl compounds for treatment of disease
    Patent number: 6852716
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals to treat diseases or conditions in which ?7 is known to be involved.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: February 8, 2005
    Assignee: Pfizer Inc
    Inventors: Daniel Patrick Walker, David W. Piotrowski, Eric Jon Jacobsen, Brad A. Acker, Jason K. Myers, Vincent E. Groppi, Jr.
  • Antiviral compounds
    Patent number: 6852731
    Abstract: The invention provides a compound of formula I: wherein G, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.
    Type: Grant
    Filed: January 14, 2003
    Date of Patent: February 8, 2005
    Assignee: Pfizer
    Inventors: Scott D. Larsen, Paul May, Karen Romines, Mark E. Schnute, Steven P. Tanis, James A. Nieman, David John Anderson, Euibong J. Kim, Steven R. Turner
  • N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
    Patent number: 6849649
    Abstract: The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R1 is optionally substituted C1-6alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C1-6alkoxy, —NR2R3 or —NR4SO2R5; X is the linkage —(CH2)n— or —(CH2)q—O— (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C1-4alkoxy; hydroxy; hydroxy(C1-3alkyl); C3-7cycloalkyl; carbocyclyl; heterocyclyl; or by C1-4alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R8 groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.
    Type: Grant
    Filed: October 28, 2003
    Date of Patent: February 1, 2005
    Assignee: Pfizer Inc.
    Inventors: Stephen Challenger, Andrew Simon Cook, Adam Thomas Gillmore, Donald Stuart Middleton, David Cameron Pryde, Alan Stobie
  • N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
    Patent number: 6849620
    Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is W0 is a bicyclic moiety and is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which ?7 is known to be involved.
    Type: Grant
    Filed: October 17, 2002
    Date of Patent: February 1, 2005
    Assignee: Pfizer Inc
    Inventors: Daniel Patrick Walker, Eric Jon Jacobsen, David W. Piotrowski, Brad A. Acker, Donn G. Wishka, Jeffrey W. Corbett, Mark R. Rauckhorst, Vincent E. Groppi, Jr.
  • Pyridazinone aldose reductase inhibitors
    Patent number: 6849629
    Abstract: The present invention relates to novel pyridazinone compounds, pharmaceutical compositions comprising those compounds and to methods of using such compounds and compositions to inhibit aldose reductase, lower sorbitol levels and, thus, lower fructose levels, and/or treat or prevent diabetic complications such as diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic microangiopathy and diabetic macroangiopathy in mammals. This invention also relates to methods of affording cardioprotection to subjects not suffering from diabetes. This invention also relates to pharmaceutical compositions and kits comprising a combination of an aldose reductase inhibitor (ARI) of this invention and a sorbitol dehydrogenase inhibitor and to methods of using such compositions or kits to treat or prevent the above diabetic complications in mammals.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: February 1, 2005
    Assignee: Pfizer, Inc.
    Inventor: Banavara L. Mylari
  • Macrolide antibiotics
    Patent number: 6849608
    Abstract: A macrolide antibiotic of the formula wherein the variables are defined as described herein.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: February 1, 2005
    Assignee: Pfizer, Inc.
    Inventors: Wei-Guo Su, Yan Chen
  • Therapeutic compositions for treating infection by Lawsonia spp.
    Patent number: 6846487
    Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis, which encodes an immunogenic polypeptide that is particularly useful as an antigen in a vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts, wherein said polypeptide is selected from the group consisting of flhB, fliR, ntrC, glnH, motA, motB, tlyC, ytfM, and ytfN polypeptides, or a homologue, analogue or derivative of any one or more of said polypeptides.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: January 25, 2005
    Assignees: Pfizer Inc., Agriculture Victoria Services Pty Ltd., Austrailian Pork Limited
    Inventors: Everett Lee Rosey, Kendall Wayne King, Robert Trygve Good, Richard Anthony Strugnell
  • Selective inhibitors of cyclooxygenase-2
    Patent number: 6846818
    Abstract: The present invention relates to cyclooxygenase-2 (COX-2) selective inhibitors of formula I: pharmaceutical compositions containing them, to their medicinal use, and to their preparations. The compounds of the invention are particularly useful in the treatment or alleviation of inflammation and inflammation associated disorders, such as, for example, rheumatoid arthritis and osteoarthritis, and in the relief of pain, such as, for example, pain associated with surgery or trauma, in mammals, preferably felines and canines.
    Type: Grant
    Filed: April 16, 2003
    Date of Patent: January 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Kristin Lundy DeMello, Brian S. Bronk, Rhonda Marie Crosson
  • Heterocyclo-alkylsulfonyl pyrazole derivatives
    Patent number: 6846930
    Abstract: The invention relates to compounds of formula 4: Wherein R1-R4 are defined as in the specification.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: January 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Dennis E. Bourassa, Michael J. Castaldi, David B. Ripin
  • One dose vaccination with Mycoplasma hyopneumoniae
    Patent number: 6846477
    Abstract: The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: January 25, 2005
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Robin Lee Keich, Lisa Grace Sabbadini
  • System and method for statistical analysis of QT interval as a function of changes in RR interval
    Patent number: 6847840
    Abstract: A system and method for statistically analyzing QT interval as a function of changes in the RR interval. The system and method utilize three statistical comparisons to fully characterize the QT response: (1) the comparison of curves to give an overall effect; (2) the incidence of points exceeding a baseline upper 95% single-point prediction bound to reflect the degree of heterogeneity of ventricular repolarization; and (3) the magnitude of these points to provide a quantitative assessment of treatment-induced changes in the QT-RR relationship. The system and method use the relationship between the QT interval and heart rate (RR interval) to reference a control baseline response. Data from mammals such as humans and dogs, and pharmacological maneuvers using both cardiac and non-cardiac therapeutic agents, may be used with this multi-parameter statistical system and method.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: January 25, 2005
    Assignee: Pfizer, Inc.
    Inventors: Michael J. DePasquale, Anthony A. Fossa, David L. Raunig
  • Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors
    Patent number: 6846820
    Abstract: This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, C(O)NR8R9 or C(O)R12, useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: January 25, 2005
    Assignee: Pfizer Inc.
    Inventors: Dennis J. Hoover, Bernard Hulin, William H. Martin, Judith L. Treadway
  • Substituted quinolin-2-one derivatives useful as antiproliferative agents
    Patent number: 6844357
    Abstract: The present invention relates to compounds of formulas 1 and 2 wherein R1, R2, R4, R5, R6, R7, R8, R10 and Z are as defined herein. The present invention also relates to pharmaceutical compositions containing the above compounds and to methods of treating hyperproliferative disorders, such as cancer, in a mammal by administering the above compounds.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: January 18, 2005
    Assignee: Pfizer Inc.
    Inventor: Bingwei V. Yang
  • Corticotropin releasing factor antagonists
    Patent number: 6844351
    Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.
    Type: Grant
    Filed: May 31, 2000
    Date of Patent: January 18, 2005
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Indole derivatives useful for the treatment of diseases
    Patent number: 6844362
    Abstract: The invention relates to indole derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The indole derivatives according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: January 18, 2005
    Assignee: Pfizer Inc
    Inventors: Alan Daniel Brown, Justin Stephen Bryans, Mark Edward Bunnage, Paul Alan Glossop, Charlotte Alice Louise Lane, Russell Andrew Lewthwaite, Simon Mantell
  • Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
    Patent number: 6844349
    Abstract: The invention relates to succinate and malonate complexes of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide having the following formula I: More particular the present invention relates to monosuccinate, hemisuccinate, sesquisuccinate and di-malonate complexes of formula I. The invention also relates to pharmaceutical compositions containing the succinate and malonate complexes of formula I. The invention further relates to methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above complexes and to methods of preparing the above complexes.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: January 18, 2005
    Assignee: Pfizer Inc
    Inventors: John C. Kath, Daniel T. Richter, Zheng J. Li, Andrew V. Trask
  • Process for preparing substituted pyridines
    Patent number: 6844441
    Abstract: A process for preparing a compound of the formula: wherein n, R1, R2, R3 and X are as defined above, used as an intermediate in the synthesis of ?-adrenergic receptor agonists.
    Type: Grant
    Filed: October 10, 2003
    Date of Patent: January 18, 2005
    Assignee: Pfizer Inc
    Inventors: Robert L. Dow, Steven R. Schneider
  • Probe holder
    Publication number: 20050005717
    Abstract: A near infrared (NIR) probe is disposed in a holder which is mounted within the wall of an enclosed process vessel. The probe reads and determines the moisture content of a product undergoing processing or drying from the enclosed vessel. The probe holder is formed with conduits, and a gas, such as air or nitrogen, is transmitted in periodic high pressure pulses through the holder conduits and transversely across the probe detecting end face to clear the probe end face of moisture and particulate contaminants to provide accurate real time moisture content determinations. The NIR probe and holder are disposed in a fluid tight construction.
    Type: Application
    Filed: May 17, 2004
    Publication date: January 13, 2005
    Applicant: Pfizer Inc
    Inventors: Marc Pensis, Wayne Byassee, Laurie Berry
  • Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6841671
    Abstract: The present invention relates to 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein said “A” is a 5-7 membered heterocyclic ring as defined in the specification and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: January 11, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark C. Noe, Martin J. Wythes, Brian S. Bronk
  • Retroviral protease inhibitors
    Publication number: 20050004230
    Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.
    Type: Application
    Filed: March 5, 2004
    Publication date: January 6, 2005
    Applicant: Monsanto Company (now named Pharmacia Corporation, which is a wholly owned subsidiary of Pfizer, Inc
    Inventors: John Talley, Daniel Getman, Gary DeCrescenzo, Kathryn Reed, Ko-Chung Lin, John Freskos, Michael Clare, Donald Rogier, Robert Heintz, Michael Vazquez, Richard Mueller